CanSino Biologics Beheer

Beheer criteriumcontroles 4/4

De CEO CanSino Biologics is Xuefeng Yu, benoemd in Jan2009, heeft een ambtstermijn van 15.83 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 3.97M, bestaande uit 64.1% salaris en 35.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 11.96% van de aandelen van het bedrijf, ter waarde € 167.59M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 3.1 jaar.

Belangrijke informatie

Xuefeng Yu

Algemeen directeur

CN¥4.0m

Totale compensatie

Percentage CEO-salaris	64.1%
Dienstverband CEO	15.8yrs
Eigendom CEO	12.0%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	3.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Xuefeng Yu's beloning veranderd ten opzichte van CanSino Biologics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-CN¥720m
Jun 30 2024	n/a	n/a	-CN¥867m
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥5m	CN¥2m	-CN¥909m

Compensatie versus markt: De totale vergoeding ($USD 548.21K ) Xuefeng } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.65M ).

Compensatie versus inkomsten: De vergoeding van Xuefeng is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Xuefeng Yu (59 yo)

15.8yrs

Tenure

CN¥3,965,000

Compensatie

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Xuefeng Yu	Co-Founder	15.8yrs	CN¥3.97m	11.96% € 167.6m
Tao Zhu	Co-Founder	15.8yrs	CN¥4.42m	7.27% € 101.9m
Dongxu Qiu	Co-Founder	15.8yrs	CN¥3.74m	11.42% € 160.1m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.5yrs	CN¥3.93m	0.0081% € 113.5k
Jing Wang	Chief Commercial Officer	3.2yrs	CN¥4.57m	0.0072% € 101.1k
Chunlin Xin	Senior Director of New Technology Department	7yrs	geen gegevens	geen gegevens
Yonghui Wu	Vice President of Marketing	no data	geen gegevens	geen gegevens
Jin Cui	Board Secretary	5.7yrs	geen gegevens	geen gegevens
Ming King Chiu	Joint Company Secretary	5.7yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CJH is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xuefeng Yu	Co-Founder	15.8yrs	CN¥3.97m	11.96% € 167.6m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.4yrs	CN¥3.93m	0.0081% € 113.5k
Jing Wang	Chief Commercial Officer	3.1yrs	CN¥4.57m	0.0072% € 101.1k
George R. Siber	Co-Chair of Scientific Advisory Board	1.8yrs	geen gegevens	geen gegevens
Shan Lu	Member of the Scientific Advisory Board	2.5yrs	geen gegevens	geen gegevens
Shuifa Gui	Independent Non-Executive Director	5yrs	CN¥300.00k	geen gegevens
Luis Barreto	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Zhi Xiao	Chairman of Employee Representative Supervisor	less than a year	geen gegevens	geen gegevens
Jianzhong Liu	Independent Non-Executive Director	5yrs	CN¥300.00k	0.00040% € 5.6k
Liming Li	Co-Chair of Scientific Advisory Board	1.8yrs	geen gegevens	geen gegevens
Jingren Zhang	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Leung Cheung Yiu	Independent Non-Executive Director	no data	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CJH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

CanSino Biologics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

High number of new directors

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Less than half of directors are independent

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

Recent updates

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Case for the Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried

Third quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.58 loss in 3Q 2023)

New minor risk - Profitability

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

High number of new directors

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

First quarter 2024 earnings released: CN¥0.69 loss per share (vs CN¥0.57 loss in 1Q 2023)

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

Full year 2023 earnings released: CN¥6.01 loss per share (vs CN¥3.68 loss in FY 2022)

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings released: CN¥5.87 loss per share (vs CN¥3.68 loss in FY 2022)

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Less than half of directors are independent

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

Less than half of directors are independent

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

Less than half of directors are independent

Full year 2022 earnings released: CN¥3.68 loss per share (vs CN¥7.74 profit in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Less than half of directors are independent

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold €414k worth of stock

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Now 31% undervalued

Third quarter 2022 earnings released

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

First quarter 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.06 loss in 1Q 2021)

Less than half of directors are independent

CanSino Biologics Inc. to Report Q1, 2022 Results on Apr 28, 2022

Cansino Biologics Inc. Proposes Dividend for the Financial Year Ended 31 December 2021

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Full year 2021 earnings released: EPS: CN¥7.74 (vs CN¥1.72 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

CanSino Biologics Inc. announces Convidecia Approve as Heterologous Booster in China

Investor sentiment deteriorated over the past week

CanSino Biologics Inc. (SEHK:6185) announces an Equity Buyback for CNY 300 million worth of its shares.

CanSinoBIO's Shows Encouraging Results for Inhaled COVID-19 Vaccine as Heterologous Booster